Dr. Udwadia is interested in all general medical problems but has special training as a chest physician. His special interests include: TB, MDR-TB, ILD, Pulmonary infections, Difficult asthma, Sleep disorders, and COVID.
He has struck the unique balance of combining a busy clinical practice with internationally acclaimed medical research. He sees over 10,000 patients annually in his extremely busy clinics many of them referred from colleagues across India.
He has over 240 PubMed indexed medical research publications and was listed amongst the top 2% of respiratory medicine researchers worldwide in the field of respiratory medicine in a Stanford University publication.
He was the first to report cases to Totally Drug Resistant TB from India. This stirred up intense medical and media attention in 2012 with 2500 articles in newspapers and news sites across the world including BBC, CNN, Reuters, Times UK, Canadian Globe, Wall Street Journal, Bloomberg, Science, Nature and a special feature on him in the prestigious Lancet.
He has been invited to deliver lectures and orations at prestigious conferences and universities around the world including the Royal Society of Medicine (London), the Royal College of Physicians (London), the European Respiratory Society, the American College of Chest Physicians, the International TB Union, and several lectures at Harvard University, Boston.
He was Invited to join the USAID India End-TB alliance and the Global TB Network (GTN) to pursue global TB elimination.
He has been advisor to the WHO, Geneva and helped formulate TB and MDR-TB guidelines.
In 2017 Open Magazine nominated him as one of their twenty five top minds for his impact on public health.
He had given two TED talks one on Drug Resistant Tuberculosis and the other on COVID-19, both of which have been widely viewed.
COVID Related activities: Since the onset of the COVID pandemic in the early months of 2020 Dr. Udwadia has been extremely busy:
- As a “hands-on” physician looking after COVID wards and ICU’s since the start of the pandemic and training the many resident doctors who work as part of his team.
- Educating doctors and medical colleagues across the country on the drug and treatment options for COVID with innumerable lectures and Zoom meetings across the globe. Special mention must be made here of: a) A WHO meeting with chief scientific advisor Dr Soumya Swaminathan, b) a session at the prestigious CROI conference, c) a guest lecture for the Australia & New Zealand Intensive care Society and d) a podcast with the editors of the prestigious NEJM.
- Actively involved in research conducting trials: a) with WHO on different drug options as part of their SOLIDARITY study, b) a trial on a novel oral anti-viral Favipiravir, c) a trial underway on the variants strains causing severe breakthrough infections, d) a trial on the incidence of pneumothorax in COVID patients in the ICU, and d) a trial auditing errors in prescriptions for home treated COVID patients before they were hospitalised.
- Since the start of the pandemic, despite his busy schedule he has continued his academic writing with around 20 PubMed indexed medical publications on COVID-19 in some of the most prestigious medical journals.
- Educating the lay public with credible articles in the Times of India, Indian Express, BBC news interviews, and an article in the FT U.K. which was one of their most widely downloaded articles. He has also been invited to deliver 2 Asia Society lectures on COVID and a TEDX talk on COVID which have been widely viewed.
- He was nominated on the Maharashtra Task Force which meets every Monday and helps the state government with COVID related medical advice.
- He is on a Core Committee of doctors elected by the Supreme Court to form a National Task Force set up to address critical COVID issues like oxygen, drugs and vaccinations.
- Lieutenant Colonel Eduljee Maneckji Damla Silver Medal in IInd M.B.B.S
- Dr. Max Lennan Scholarship in IIIrd M.B.B.S.
- Dr. D.R. Bardi Gold Medal and Book Prize in IIIrd M.B.B.S.
- The Mancherji P. Choksey Memorial Gold Medal in IIIrd M.B.B.S.
- The Dr. Govind Vishnu Juvekar Prize in IIIrd M.B.B.S.
- The Dr. A.J. Kohiyar Prize 1984 for standing 1st in the IIIrd M.B.B.S Examinations in Medicine amongst Post-Graduate registered students in medicine.
- The Dr. A.J. Kohiyar Oration delivered on 29th March 1985 under the auspices of “The Research Society” of Grant Medical College at its Annual Conference.
- The Dr. Swamy award for the best Post-Graduate thesis submitted for the M.D. exams.
- The Searle Award for the best original research paper presented at the 43rd Annual Conference of the Cardiology Society of India, November 22, 1991.
- He was listed amongst the top 2% of respiratory medicine researchers worldwide in the field of respiratory medicine in a Stanford University publication.
- He was Invited to join the USAID India End-TB alliance and the Global TB Network (GTN) to pursue global TB elimination.
- He has been advisor to the WHO, Geneva and helped formulate TB and MDR-TB guidelines.
- In 2017 Open Magazine nominated him as one of their twenty five top minds for his impact on public health.
- He had given two TED talks one on Drug Resistant Tuberculosis and the other on COVID-19, both of which have been widely viewed.
He has been invited to deliver lectures and orations at prestigious conferences and universities around the world including the Royal Society of Medicine (London), the Royal College of Physicians (London), the European Respiratory Society, the American College of Chest Physicians, the International TB Union, and several lectures at Harvard University, Boston.
He has over 240 PubMed indexed publications, the majority of them international, in every important medical journal, including: Lancet, Lancet-ID, New England Journal of Medicine, British Medical Journal, Clinical Infectious Disease, Thorax, American Journal of Respiratory & Critical Care Medicine. (www.ncbi.nlm.nih.gov/pmc/).
A. PUBLICATIONS: TEXTBOOKS AUTHORED:
Principles Of Respiratory Medicine. Oxford International Press. 2011.
Puzzling Cases in Pulmonary Medicine. Tree Life Media 2017.
B. PUBLICATIONS: CHAPTERS IN INTERNATIONAL TEXTBOOKS
Chapters on Asthma and ARDS in: Principles of Critical Care (by F.E.Udwadia, Oxford University Press)
Chapter on Tuberculosis in India in: Clinical Tuberculosis (ed :P. D. O Davies, Chapman Hill publishers)
Chapter in Case Presentations in Clinical Tuberculosis (eds. P.D.O Davies, L.P. Ormerod, Arnold Publishers)
Chapters on COPD, Lung Cancer, and Mediastinal tumors in Medical Therapeutics
Chapter on Pregnancy and the Lung in Obstetric Medicine. (eds. U. Krishna and N. Sheriar, Orient-Longman)
Chapter on Hypersensitivity Pneumonia in ‘Allergy and Asthma; a tropical view’ (ed. W. Shaikh, IJCP)
Chapter on Community Acquired Pneumonia in Textbook of Respiratory Medicine: An Asian Perspective (eds. IP M, Chan-Leung M, Lam WK, Zhong NS)
Chapter on Legionella Pneumonia in API Textbook of Medicine 7th ed 2003 (ed Shah S)
Chapter on Epidemiology of OSA in India in Practical Approach to Critical Respiratory Medicine. (Ed Arora VK) 2006
Chapter on Tropical Respiratory Disease in Respiratory Infections (eds Torres A, Ewig S, Mandell L, Woodhead M) 2006
Chapter on Interstitial lung disease in a resource limited setting: the case of India. In Interstitial Lung Disease. Monograph 46, European Respiratory Society.
PUBLICATIONS IN PUBMED INDEXED JOURNALS:
1. Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis.
Lancet Infect Dis. 2025 Jun 5: S1473-3099(25)00157-4. doi: 10.1016/S1473-3099(25)00157-4.
2. Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis.
The MDR-TB MUKT and Indo-South Africa Study Teams; MDR-TB MUKT and Indo-South Africa Study Teams. Antimicrob Agents Chemother. 2025 Oct;69(10): e0010125. doi: 10.1128/aac.00101-25. Epub 2025 Sep 2.
3. Nikshay Poshan Yojana for all TB patients: Difficulties in access for multidrug-resistant TB patients.
Indian J Tuberc. 2025 Jul;72(3):282. doi: 10.1016/j.ijtb.2024.11.003. Epub 2024 Nov 19.
4. Global epidemiology and burden of interstitial lung disease. Lancet Respir Med. 2025 Aug;13(8):739-755. doi: 10.1016/S2213-2600(25)00129-8. Epub 2025 Jul 17.
5. Clinical best practices for caring for people with expanded resistance to newer TB drugs. IJTLD Open. 2025 Jun 13;2(6):315-323. doi: 10.5588/ijtldopen.25.0240. eCollection 2025 Jun.
6. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12;392(22):2203-2214. doi: 10.1056/NEJMoa2503643. Epub 2025 May 19.
7. The Madras trial and TB sanatoria. J Infect Dis. 2025 May 17: jiaf254. doi: 10.1093/infdis/jiaf254. Online ahead of print
8. Impact of COVID-19 on diagnosis of tuberculosis and tuberculosis infection in South America, Asia, and Africa. J Bras Pneumol. 2024 Jul 8;50(3): e20240077. doi: 10.36416/1806-3756/e20240077.
9. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2.
10. Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort. Global Tuberculosis Network and TB/COVID-19 Global Study Group; Eur Respir J. 2023 Nov 29;62(5):2300925. doi: 10.1183/13993003.00925-2023.
11. Treating household contacts of MDR-TB patients: Are we being too hasty? Lung India. 2023 Sep-Oct;40(5):404-405. doi: 10.4103/lungindia.lungindia_377_23.
12. Occupational interstitial lung diseases. J Intern Med. 2023 Dec;294(6):798-815. doi: 10.1111/joim.13707. Epub 2023 Aug 7.
13. Recent advances in the treatment of tuberculosis. Clin Microbiol Infect. 2024 Sep;30(9):1107-1114. doi: 10.1016/j.cmi.2023.07.013. Epub 2023 Jul 22.
14. COVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health. Asia Pac Allergy. 2023 Mar;13(1):44-49. doi: 10.5415/apallergy.0000000000000021. Epub 2023 Apr 28.
15. Clinical standards for the management of adverse effects during treatment for TB. Int J Tuberc Lung Dis. 2023 Jul 1;27 (7):506-519. doi: 10.5588/ijtld.23.0078.PMID: 37353868
16. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
Rheumatology (Oxford). 2024 Mar 1;63(3):639-647. doi: 10.1093/rheumatology/kead280.PMID: 37294870
17. Optimal management of drug-resistant tuberculosis: Can India lead the way? Indian J Med Res. 2023 Feb-Mar;157(2&3):220-222. doi: 10.4103/ijmr.ijmr_300_23.
18. Swimming against the STREAM: Why STREAM 2 data cannot be easily applied to MDR-TB patients across India. Lung India. 2023 May-Jun;40(3):290-291. doi: 10.4103/lungindia.lungindia_74_23.
19. New treatments for Drug Resistant TB: Past imperfect, future bright. Lung India. 2023 Jan-Feb;40(1):1-3. doi: 10.4103/lungindia.lungindia_556_22
20. Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India. Front Pharmacol. 2023 Jan 4; 13:1081123. doi: 10.3389/fphar.2022.1081123. eCollection 2022.
21. Severe interstitial lung disease persisting 2 years post-COVID-19 despite anti-fibrotic therapy.
Lung India. 2022 Nov-Dec;39(6):587-588. doi: 10.4103/lungindia.lungindia_355_22.
22. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023 Mar 30;61(3):2103187. doi: 10.1183/13993003.03187-2021. Print 2023 Mar.
23. Prognosis of Spontaneous Pneumothorax/Pneumomediastinum in Coronavirus Disease 2019: The CoBiF Score. J Clin Med. 2022 Nov 30;11(23):7132. doi: 10.3390/jcm11237132.
24. Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up survey. Clin Exp Allergy. 2022 Aug;52(8):965-973. doi: 10.1111/cea.14191.
25. Clinical standards for drug-susceptible pulmonary TB. Int J Tuberc Lung Dis. 2022 Jul 1;26(7):592-604. doi: 10.5588/ijtld.22.0228.
26. Clinical standards for the dosing and management of TB drugs. Int J Tuberc Lung Dis. 2022 Jun 1;26(6):483-499. doi: 10.5588/ijtld.22.0188.
27. Genomics of postvaccination SARS-CoV-2 infections during the Delta dominated second wave of COVID-19 pandemic, from Mumbai Metropolitan Region (MMR), India. J Med Virol. 2022 Sep;94(9):4206-4215. doi: 10.1002/jmv.27861. Epub 2022 May 25. PMID: 35578378
28. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. WHO Solidarity Trial Consortium.Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2.
29. Genetic insight into Birt-Hogg-Dubé syndrome in Indian patients reveals novel mutations at FLCN.
Orphanet J Rare Dis. 2022 Apr 27;17(1):176. doi: 10.1186/s13023-022-02326-5.PMID: 35477461
30. Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clin Infect Dis. 2022 Dec 19;75(12):2201-2210. doi: 10.1093/cid/ciac322.PMID: 35476134
31. Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. J Bras Pneumol. 2022 Apr 20;48(2): e20220087. doi: 10.36416/1806- 3756/e20220087. eCollection 2022.
32. Correction to: Reply to van Deun and Decroo. Clin Infect Dis. 2022 May 30;74(10):1891. doi: 10.1093/cid/ciac241.PMID: 35459941 No abstract available.
33. Editorial: Interstitial Lung Disease Around the World. Front Med (Lausanne). 2022 Mar 18;9:865334. doi: 10.3389/fmed.2022.865334. eCollection 2022.
34. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med. 2022 Jun;10(6):603-622. doi: 10.1016/S2213-2600(22)00092-3. Epub 2022 Mar 23.
35. Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group. Lung India. 2022 Mar-Apr;39(2):177-186. doi: 10.4103/lungindia.lungindia_659_21.
36. Increased Moxifloxacin Dosing Among Patients with Multidrug-Resistant Tuberculosis with Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India.
37. Open Forum Infect Dis. 2021 Dec 23;9(2): ofab615. doi: 10.1093/ofid/ofab615. Collection 2022 Feb.
38. Cycloserine did not increase depression incidence or severity at standard dosing for MDR-TB. Eur Respir J. 2021 Dec 23:2102511. doi: 10.1183/13993003.02511-2021. Online ahead of print.
39. Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016. Clin Infect Dis. 2021 Dec 6;73(11):e3929-e3936. doi: 10.1093/cid/ciaa621.
40. Tuberculosis and COVID-19 co-infection: description of the global cohort. TB/COVID-19 Global Study Group. Eur Respir J. 2021 Nov 11:2102538. doi: 10.1183/13993003.02538-2021. Online ahead of print.
41. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. Ong CWM; Global Tuberculosis Network. Eur Respir J. 2021 Nov 11;58(5):2101786. doi: 10.1183/13993003.01786-2021. Print 2021 Nov.
42. Increased frequency of pneumothorax and pneumomediastinum in COVID-19 patients admitted in the ICU: A multicentre study from Mumbai, India. Clin Med (Lond). 2021 Nov;21(6):e615-e619. doi: 10.7861/clinmed.2021-2020.
43. India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further. Lung India. 2021 Nov-Dec;38(6):590-591. doi: 10.4103/lungindia.lungindia_425_21.
44. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021 Oct 1;25(10):797-813. doi: 10.5588/ijtld.21.0425.
45. Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? - Authors' reply. Lancet Infect Dis. 2021 Oct;21(10):1350. doi: 10.1016/S1473-3099(21)00480-1. Epub 2021 Aug 24.
46. Understanding the Potential Impact of Different Drug Properties on SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis. Hallett TB.Clin Infect Dis. 2021 Sep 21: ciab837. doi: 10.1093/cid/ciab837. Online ahead of print.
47. Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2021 Sep 5;19(1):220. doi: 10.1186/s12916-021-02111-4.
48. Asia-Pacific perspectives on the COVID-19 pandemic.
49. APAAACI COVID-19 Working Group.Allergy. 2021 Sep;76(9):2998-2901. doi: 10.1111/all.14894. Epub 2021 May 18..
50. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021 Sep-Oct;27(5):403-412. doi: 10.1016/j.pulmoe.2021.02.006. Epub 2021 Mar 19.
51. Contextualizing evidence-based recommendations for the second wave of the COVID-19 pandemic in India. Lancet Infect Dis. 2021 Jul;21(7): 905-907.doi:10.1016/S1473-3099(21)00329-7. Epub 2021 Jun 8.
52. Sorry for the delay. Clin Microbiol Infect. 2021 Jul;27(7):941-943. doi: 10.1016/j.cmi.2021.03.007. Epub 2021 Apr 3.
53. Reply to van Deun and Decroo. Clin Infect Dis. 2021 Jun 15;72(12): e1168-e1169. doi: 10. 10.1093/cid/ciaa1875.
54. Audio Interview: India's Covid-19 Crisis. Engl J Med. 2021 May 6;384(18): e84. doi: 10.1056/NEJMe2107728.
55. The Case Against Tocilizumab. J Assoc Physicians India. 2021 Apr: 69(4) :11-12.
56. Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al. Int J Infect Dis. 2021 Apr; 105:686-687. doi: 10.1016/j.ijid.2021.02.028. Epub 2021 Feb 15.
57. COPD Management during the COVID-19 pandemic. Lung India 2021. Mar: 38 (Supplement): S80-S85. doi: 10.4103/lungindia.lungindia_685_20.
58. Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids. Lung India.2021 Mar;38 (Supplement):S61-S63. doi: 10.4103/lungindia.lungindia_533_20.
59. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021 Mar;38(Supplement): S41-S47.doi: 10.4103/lungindia.lungindia_818_20.
60. The impact of COVID-19 on patients with preexisting interstitial lung disease: High mortality in these high-risk patients. Lung India. 2021 Mar;38(Supplement):S1-S3. doi: 10.4103/lungindia.lungindia_60_21.
61. Clinical and Molecular Findings in Mendelian Susceptibility to Mycobacterial Diseases: Experience from India. Front Immunol. 2021 Feb 25; 12:631298. doi: 3389/fimmu.2021.631298. eCollection 2021.
62. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021 Feb; 103:62-71. doi: 10.1016/j.ijid.2020.11.142. Epub 2020 Nov 16
63. Effective use of telemedicine in Mumbai with a cohort of extensively drug-resistant "XDR" tuberculosis patients on bedaquiline during COVID-19 pandemic. Lung India. 2021 Jan-Feb;38(1):98-99. doi: 10.4103/lungindia.lungindia_464_20.
64. TB and COVID-19 co-infection: rationale and aims of a global study. Int J Tuberc Lung Dis. 2021 Jan 1;25(1):78-80. doi: 10.5588/ijtld.20.0786.
65. Safety of Rifabutin in patients with rifampicin-induced thrombocytopenia.Lung India. 2020 Sep.
66. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020 Sep 2.
67. COVID-19 care in India: the course to self-reliance. Lancet Glob Health. 2020 Nov;8(11): e1359-e1360. doi:10.1016/S2214-109X (20)30384-3. Epub 2020 Aug 24.
68. Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP).Jul-Aug 2020;37(4):359-378. doi: 10.4103/lungindia.lungindia_275_20.
69. From pulmonary susceptible tuberculosis to extensively drug-resistant tuberculosis: An interesting case report of a young Indian girl. Indian J Tuberc. 2020 Jul.
70. Prognostic Factors for Adverse Outcomes in COVID-19 Infection. J Assoc Physicians India. 2020 Jul;68(7):62-66
71. Clofazimine: an old drug for never ending diseases, Future Microbiol. 2020 May; Epub 2020 Jun 2020
72. Hydroxychloroquine for COVID-19: What is our Current State of Knowledge? J Assoc Physicians India. 2020 Jun;68(6):48-52.
73. How to protect the protectors: 10 lessons to learn for doctors fighting the COVID-19 coronavirus. Med J Armed Forces India. 2020 Apr
74. Drug associated adverse events in the treatment of multidrug resistant tuberculosis: an individual patient data meta-analysis, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017.Lancet Respir Med. 2020 Apr.
75. Challenging the management of drug-resistant tuberculosis – Author’s reply 2020. Jr.Lancet. 2020 Mar
76. MDR/XDR –TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis network, 2020. Int J Infect Dis. 2020 Mar
77. Reply to van Deun and Decroo, 2020
78. Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016, 2020.
79. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020, 2020
80. Effective use of telemedicine in Mumbai with a cohort of extensively drug-resistant "XDR" tuberculosis patients on bedaquiline during COVID-19 pandemic. 2020
81. COVID-19 -Tuberculosis interactions: When dark forces collide, 2020
82. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, 2020
83. The N-95 mask: invaluable ally in the battle against the COVID-19 pandemic, 2020 Jul-Aug 2020
84. Hydroxychloroquine for COVID-19: What is our Current State of Knowledge? 2020
85. Prognostic Factors for Adverse Outcomes in COVID-19 Infection, 2020
86. How to protect the protectors: 10 lessons to learn for doctors fighting the COVID-19 coronavirus, 2020
87. Safety of Rifabutin in patients with rifampicin-induced thrombocytopenia,2020
88. COVID-19 care in India: the course to self-reliance,2020
89. From pulmonary susceptible tuberculosis to extensively drug-resistant tuberculosis: An interesting case report of a young Indian girl, Indian J Tuberc. 2020 Jul.
90. Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India, 2020. J Clin Tuberc Other Mycobact Dis. 2020 Jul
91. Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP).2020
92. Neuropsychiatric reactions induced by cycloserine in the treatment of multi-drug-resistant tuberculosis: what an Indian female patient tells us, BMJ Case Rep 2019
93. Outcomes of patients with drug- resistant tuberculosis treated with bedaquiline containing regimens and undergoing adjunctive surgery, J Infect 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7.
94. Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection, 2019
95. Use of Nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience, Lung India, 2019.
96. Starting the conversations CRISPR’S role in India,2019
97. A shorter Regimen for Ripampin-Resistant Tuberculosis,N Engl, J Med., 2019. N Engl J Med. 2019 Sep 12;381(11): e22. doi: 10.1056/NEJMc1905782
98. Management of drug-resistant tuberculosis, Lancet 2019
99. Pulmonary drug –resistant tuberculosis and surgery: report of 39 patients treated in a tertiary care hospital in Mumbai, thorax 2019.
100. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med.,
101. Few eligibles for the newly recommended short course MDR TB regime at a large Mumbai private clinic, BMC Infect Dis, 2019. Jan 28;19(1):94. doi: 10.1186/s12879-019-3726-8.
102. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India, 2019 Indian J Tuberc. 2019 Jan;66(1):87-91. doi: 10.1016/j.ijtb.2018.04.011. Epub 2018 Apr 17.
103. Surveillance of adverse events in the treatment of drug-resistant tuberculosis A global feasibility study, Int J Infect Dis, 2019 Eur Respir J. 2019 Dec 19;54(6):1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec
104. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres., 2019
105. Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans, Antimicrob Agents Chemother 2019 Sep 23;63(10): e00913-19. doi: 10.1128/AAC.00913-19. Print 2019 Oct.
106. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease, 2019
107. Treatment correlates of successful outcomes in pulmonary multidrug- resistant tuberculosis – an individual patient data meta-analysis, Lancet 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-736(18)31644-1.
108. Tuberculosis in South Asia: a tide in the affairs of men. Multidiscip Respir Med.2018 Mar 22; 13:10: doi:10.1186/s40248-018-0122-y. eCollection2018
109. Revising the definition of extensively drug-resistant tuberculosis,2018
110. Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India. Eur Respir J. 2017 Mar 22;49(3). pii: 1601699.
111. Interstitial Lung Disease in India. Keep Searching and You'll Keep Finding. Am J Respir Crit Care Med. 2017 Mar 15;195(6):714-715.
112. Failure to reach therapeutic levels of rifampicin and isoniazid by recommended dosages. .Infect Dis (Lond). 2017 Jul;49(7):552-555.
113. Drug-resistant tuberculosis:An update on disease burden, diagnosis and treatment. Respirology 2018 Jul 23(7):656-673.doi:10 1111/resp.13304.
114. Bronchoalveolar lavage contamination by sterile containers: A unique and unrecognized cause of a false positive galactomannan Kathar SS, Mullerpattan J, Shetty A, Udwadia ZF. Lung India. 2017 Nov Dec;34(6):572-573.
115. Importance of Therapeutic Drug Monitoring of Rifampicin. J Assoc Physician India 2016 Aug 64 Aug 64 Aug 64 64-72).
116. Who will teach the teachers : An analysis of the inhaler technique of Indian patients and health care providers in a tertiary health care centre. Lung India. 2016 Sep-Oct;33(5):493-5.
117. Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai. Lung India 2016 May-Jun; 3.3(3):253-6,
118. Mobility patterns of persons at risk for drug-resistant tuberculosis in Mumbai, India. Int J Tuberc Lung Dis. 2016 Dec;20(12):1633-1638.
119. BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers Clin Infect Dis. 2016 May 15:62 Suppl 3: S262-7 Tuberculosis in India BMJ. 2015 Mar 23;350.
120. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India. 2015 Jan-Feb;32(1):50-2.
121. Multidrug- resistant-tuberculosis treatment in the Indian private sector, Results from a tertiary referral private hospital in Mumbai Lung India. 2014 Oct;31(4):336-41.
122. Tropical pulmonary eosinophilia - a review. Indian J Med Res 2013. 138:3;295-302.
123. The association of diabetes and tuberculosis: impact on treatment and post- treatment outcomes. Thorax 2013:68(3):202-203.
124. Resistance to second-line drugs in multi-drug resistant tuberculosis. Lancet 2013;381:625-626.
125. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J. 2013:42:288-290.
126. Xpert MTB/RIF and pulmonary tuberculosis: time to delve deeper? Thorax 2013;68:987-988.
127. Macitentan and morbidity and mortality in pulmonary artery hypertension. N Eng J Med 2013;369:809-818.
128. Nomenclature of drug-resistant tuberculosis. Lancet Infect Dis. 2013; 11:917.
129. Early bactericidal activity of new drug regimens for tuberculosis. Lancet 2013:381:111-112
130. Totally drug-resistant TB in India: every dark cloud has a silver lining. Journal Epidemiology and Community Health. 2013:67:6:471-472.
131. Advances in tuberculosis 2011-2012. Thorax 2013
132. Disseminated tuberculosis with immune thrombocytopenic purpura. Lung India. 2012:1;63-65.
133. Adverse effects among HIV/MDR-TB co-infected patients receiving Anti-retroviral and second-line anti TB treatment in Mumbai, India. PLoS ONE: 2012:7:7:e40781.
134. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Resp J 012
135. The added effect of thioridazine in treatment of resistant tuberculosis. IUATLD 2012
136. Point of care breath test for bio markers of active pulmonary tuberculosis. Tuberculosis (Edinb) 2012:92:4:314-318.
137. MDR TDR XDR Tuberculosis: ominous progression. Thorax, Editorial, April 2012
138. Totally drug-resistant tuberculosis in India: who let the djinn out? Respirology: 2012:17:5:74-75.
139. Why 'STOP TB' is incomplete without quit smoking. Indian J Chest Dis Allied Sci. 2011; 53: 9-10.
140. Statins and the lung: hope or hype? Indian J Chest Dis Allied Sci. 2011
141. Primary immune deficiency in the ICU: it is never too late to diagnose and treat. Indian J Crit Care Med. 2011:15:3;179-181.
142. Prevalence of venous thromboembolism in acute exacerbations of chronic obstructive lung disease: an Indian perspective. Indian J Chest Dis and Allied Sciences. 2011:53;207-210.
143. TB masquerading as community acquired pneumonia. Respiratory Medicine CME. 2011.
144. Evaluation of light emitting diode-based fluorescence microscopy for the detection of mycobacteria in a tuberculosis-endemic region. Int J Tuberc Lung Dis 2011. 15(4): 483-488.
145. Universal access for MDR-TB limited without the involvement of the private sector. Int J Tuberc Lung Dis. 2011
146. Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discovery. 2011. 1:6; (2): 88-91.
147. Clonal population of Mycobacterium Tuberculosis strains reside within multiple lung cavities. PLoS one 2011:6;9:e24770
148. Totally Drug-Resistant Tuberculosis in India. Clin Infect Dis 2011
149. Thioridazine cures extensively drug resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents. 2010;35:5:524-526. (Editorial).
150. Assessment of linezolid efficacy and safety in MDR and XDR-TB: an Indian perspective. Eur Respir J. 2010;35:4:936-938.
151. Pleural tuberculosis: an update. Current Opinion in Pulmonary Medicine. 2010 Jul;16(4):399-406.
152. Private patient perceptions about a public programme: what do private Indian tuberculosis patients really feel about directly observed treatment? BMC Public Health. 2010 Jun 22; 10(1): 357.
153. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades. PLoS ONE Aug 2010. Vol 5: Issue 8: e12023
154. Tumor necrosis alpha-blocker induced tuberculosis. J Rheumatol 2010: 37::7: 1542.
155. Why covering all in the DOTS program is not the same as all being covered by DOTS program. Lung India 2010: 27: (4) : 261.
156. LABAs and asthma: from the SMART study to the SMART approach. Ind J of Chest Dis Allied Sci 2010; 52: 191-193.
157. Retrospective study of ILD in a tertiary care center in India. Indian J Chest Disease Allied Science. 2010; 52: 191-193.
158. Tuberculosis and diabetes mellitus: merging epidemics. JAPI 2009:57:399-404. Review.
159. A 12-year-old girl with Hodgkin’s disease presenting as a non-reolving pneumonia and an endobronchial nodule. Indian J Chest Dis Allied Sci. 2009;51:4:241-243.
160. Oxaplatin induced lung fibrosis. Indian J Med Paediatric Oncology. 2009;30:116-118.
161. Increasing incidence of fluoroquinolone-resistant mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009:1: 79-83.
162. Normal chest radiographs in sputum culture positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009:1: 148-149.
163. A 24 year old man with giddiness, hemoptysis and skin lesions. Chest 2008: 134: 5; 1084-1087.
164. Cryptogenic Organising Pneumonia: clinical profile in a series of 34 admitted patients in a hospital in India. J Assoc Physicians India. 2008: 229-232
165. Multiple Microscopic Pulmonary Arterio-Venous Malformation. Indian J of Chest Disease.2008:237-239.
166. Hypereosinophilic syndrome with isolated Loefflers Endocarditis; complete resolution with corticosteroids. Journal of Postgraduate Medicine. 2008 117-119.
167. Idiopathic pulmonary haemosiderosis: complete remission with steroids. Indian J Chest Dis Allied Sci 2008:50: 289-291.
168. Hypereosinophilic syndrome with isolated Loefflers endocarditis. J Postgrad Med 2008: 54; 2: 135-137.
169. Idiopathic pulmonary hemosiderosis: complete remission with steroids. Indian J Chest Disease Allied Sciences. 2008: 50; 3: 289-291.
170. Cryptogenic organizing pneumonia: clinical profile. JAPI 2008: 56; 229-232.
171. XDR-TB in India: when will we heed the alarm? JAPI. 2008: 134:5; 1084-1087. Editorial.
172. XDR Tuberculosis in India: what’s in a name? Lancet ID 2007:7:441-442.
173. The politics of TB: the politics, economics and impact of directly observed treatment in India. Chronic Respiratory Disease 2007: 4 (2): 101-106.
174. Images in clinical medicine: Pulmonary alveolar proteinosis. N Eng J Med 2007: 357: 19.
175. The burden of undiagnosed airflow obstruction in India. Editorial. J Assoc Physicians India. 2007:55; 547-548.
176. Resection of an endobronchial hamartoma by electrocautery and argon plasma ablation via fibreoptic bronchoscope. Indian Journal of Chest Diseases & Allied Sciences 2006; 48: 217-219
177. Pulmonary hyalinizing granuloma with ureteric fibrosis: a case report and review of relevant literature Indian Journal of Chest Diseases & Allied Sciences 2006; 48: 283-285
178. MDR-TB in the era of HIV. Journal of Internal Medicine. 2006; 18: 4; 33-36.
179. Multidrug resistant tuberculosis in Mumbai: its only getting worse. Int J Tuberc Lung Dis 2006; 10:1421-1422.
180. High incidence of the Beijing Genotype among multidrug resistant isolates of Mycobacterium Tuberculosis in a tertiary referral centre in Mumbai, India. Clinical Infectious Diseases 2005: 40: 881-886.
181. Utility of the antigen-specific interferon- γ assay for the management of tuberculosis. Current Opinion in Pulmonary Medicine 2005: 11: 195-202.
182. Application of multiplex ARMS and SSCP/HD analysis in molecular diagnosis of cystic fibrosis in Indian patients. Molecular Diagnosis 2005: 9 (2) 59-66.
183. Urban Indian men have the highest prevalence of obstructive sleep apnea in the world. Chest India, 2005; 6,4: 189-191. Editorial.
184. Pneumocystis carrini pneumonia in HIV infected patients from Mumbai. JAPI 2005: 53; 437-440.
185. Follicular bronchiolitis in a patient with rheumatoid arthritis. J Indian Rheumatology Association 2004: 12: 74-76.
186. Upper airways involvement in Wegener’s granulomatosis. A case report and review. J. Indian Rheumatology Association. 2004: 12:
187. Prevalence of sleep disordered breathing and sleep apnea in middle-aged urban Indian men. Am J Respir Crit Care Med 2004: 169; 168-173.
188. Pneumocystis Carinii infection in the developing world. New Eng J of Med 2004
189. Controlling tuberculosis in India. New Eng J Med 2003; 348(8): 758-759.
190. Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis 2003:36: (12); e152-154.
191. Etiology of community acquired pneumonia in India. Eur Resp J 2003: 544s
192. CAP in India: What bugs? What tests? What drugs? Int J Tuberc Lung Dis 2003:7; 11: s132-s133.
193. Molecular diagnosis of cystic fibrosis in Indian patients – a preliminary report. J Assoc Physicians India 2003; 51: 345-348.
194. Controlling TB in India; everything is not what it seems. Chest India. 2003; 4;(2): 59-60.
195. ARDS: Predicting mortality and improving survival. J Assoc Physicians India. Editorial 2003:51: 849-850.
196. IP-10 in interstitial lung disease of systemic sclerosis. J Indian Rheumatology Association 2003: 11: 2-4.
197. Health seeking behaviour among tuberculosis patients in rural South Africa. Int J Tuberc Lung Dis 2002; 6 (4): 365-366.
198. Drug resistant tuberculosis in India. Int J Tuberc Lung Dis 2002; 6 (11): 1033.
199. A profile of sarcoidosis from a private hospital in Bombay. Chest 2002; 122:4: 146s-147s
165. Antibiotic use and abuse in the ICU; an Indian perspective. Editorial Chest-India.
166. Current anti-tuberculous drugs and protocols in MDR-TB. The Indian Practitioner. 2001; 54:3 191-196.
167. Lymphocytic interstitial pneumonia associated with autoimmune hepatitis. Indian Journal of Gastroenterology. 2001; 20: 76-77.
168. Prader Willi syndrome with sleep disordered breathing: effect of two years nocturnal CPAP. Indian J Chest Diseases & Allied Sciences. 2001. 43: 51-53.
169. Spontaneous resolution of diffuse alveolar septal amyloidosis. Indian J Chest Diseases & Allied Sciences. 2001.
170. Enumeration of T cells specific for RD1-encoded antigens: a novel approach to estimating the prevalence of latent M. tuberculosis infection. Journal of Infectious Disease.2001; 183: 469-477.
171. Fatal cerebral air embolism as a complication of transbronchial lung biopsy: a case report. Australasian Radiology. 2001; 45:215-217.
172. Massive pleural effusion as the presenting feature of a subarachanoid- pleural fistula. Respiration (Karger). 2001; 870: 1-7.
173. Nebulised alpha interferon is effective in Indian patients with MDR-TB. Am J of Resp and Crit Care Medicine.2001; 163: 5: A103.
174. India’s multi-drug-resistant tuberculosis crisis. Ann NY Acad Sci 2001. 953: 98-105.
175. Pulmonary disorders in the 21st century. The Indian Practitioner. January 2000; 53:1:25-30.
176. Pneumocystis pneumonia: Taming the beast. Editorial, The Indian practitioner. 1999; 52: 9; 593-594.
177. Role of bedside bronchoscopy in ICU patients. The Journal of General Medicine 1999; 11:32-34.
178. Cryptogenic organising pneumonia presenting as bilateral non-resolving pneumonia. Current Medical Trends. July 1999; 577-580.
179. Hepatic sarcoidosis responding to chloroquine as a steroid-sparing drug. Indian Journal of Gastroentrology 1999; 18: 177-178
180. Mediastinal hibernoma. European Journal of Cardiothoracic Surgery. 1999; 15:533-535.
181. Responses to a sleep questionnaire in 300 Indians attending routine health screening. Thorax. 1999; 54: 7: A47.
182. Pulmonary alveolar proteinosis with respiratory failure-therapeutic role of bronchoscopic and whole lung lavage. JAPI 1998; 46: 738-739.
183. Tracheal Rhinosporidiosis J of Bronchology. Vol 5 No. 1 Jan 1998: 57-58
184. Role of bronchoscopy in an Indian critical care unit: an experience of 118 procedures. Thorax Dec. 1997; 52: suppl. 6: A65.
185. Recurrent familial jaundice due to benign intrahepatic cholestasis. JAPI 1997, Vol 45, 1: 59-60
186. Chronic occult gastroesophageal reflux leading to interstitial pulmonary fibrosis. JAPI 1997, vol.45:6;495-496
187. Recent advances in respiratory medicine. Journal of General Medicine. Dec.96 Vol 9; 1: 17-20.
188. Rabies: an update. New England J of Medicine.
189. Pneumothorax as the presenting manifestation of lymphangitis carcinomatosis. Journal of the Association of Physicians of India (JAPI) Vol 42 1994: 904-906.
190. Churg Strauss Syndrome. Journal of the Association of Physicians of India (JAPI) 1994; 42; 4: 341-2.
191. Shrinking lungs in SLE: Journal of Indian Rheumatology Association 1994, Vol 2, No 4; 85-89.
192. Rifampicin induced worsening of steroid-dependent asthma. Respiratory Medicine (UK) 1993; 87:629.
193. Thyrotropin concentration predicts outcome in critical illness. Anaesthesia. 1993; 48 (5): 373-376.
194. Use of nasal ventilation to facilitate weaning in patients with chronic respiratory insufficiency. Thorax September 1992; 47 : 715-718.
195. Hemodynamic studies during the management of severe tetanus. Quarterly Journal of Medicine 1992; 83: 302.
196. Early detection of right ventricular dysfunction in severe chronic obstructive disease
197. Cortisol response to corticotropin and survival in septic shock. Critical Care Medicine 1991; 19: 589-590.
198. Cortical response to corticotrophin and survival in septic shock. Lancet 1991; 337: 583-583.
199. Bronchoscopic and bronchographic finding in sarcoidosis. Respiratory Disease Digest (Abstract) 1991; 2: 7-8
200. Prognostic value of admission thyrotrophin levels in intensive care patients. Intensive Care Medicine (Abstract) 1991
201. The cortisol response to ACTH in septic shock. Intensive Care Medicine (Abstract) 1991
202. Specialist care versus generalist care. British Thoracic Society Newsletter 1991; 7: 6-7.
203. Value of non-invasive nasal positive pressure ventilation in weaning intubated patients from conventional intermittent positive pressure ventilation. European Respiratory Journal 1991: Vol 4, Supplement 14:
pg 1985.
204. APACHE II expected outcome calculations are subject to inter-observer variation. Anaesthesia 1990; 45: 888-889.
205. Autonomic dysfunction in severe tetanus. Intensive care Medicine.1990; 16(8): 520
206. An attempt to determine the optimal duration of hospital stays following a severe attack of asthma. Journal of the Royal College of Physicians of London 1990;24 : 112-114.
207. Bronchoscopic and bronchographic findings in 12 patients with sarcoidosis and sarcoidosis and severe or progressive airways obstruction. Thorax 1990;45:272-275
208. Idiopathic portal hypertension. New England. Journal of Medicine. 1990; 322:273-274.
209. Cardiac arrest telephone numbers. Lancet. 1990;355-407.
210. Confusing serological abnormalities in bird fancier’s lung; lesson of the week. British Medical Journal – 1990, 300: 1519
211. Associated anomalies in a retrospective study of 43 cases of gynatresia. Journal of the Association of Physicians of India. January 1989 (Abstract)
212. Human rabies: Clinical features, diagnosis, complications and management. Critical Care Medicine. 1989; 17: 834-836.
213. What is the optimal duration of hospital stay after an acute attack of asthma? Thorax. 1989 ; 44 : 839-840p (abstract)
214. Bronchoscopic and bronchographic findings in 11 patients with sarcoidosis and severe or progressive airways obstruction. Thorax 1989; 44: 846p(abstract)
215. A study of antithyroglobulin antibodies in 900 India patients with thyroid disease. Journal of the Association of Physicians of India. January 1988 (Abstract)
216. Studies conducted in nine individuals exposed to intermittently over a period of two years to Danazol. Journal of Association of Physicians of India. January 1988 (Abstract)
217. Penile hyper-excitability with recurrent ejaculation as the presenting manifestation of a case of rabies. Post-graduate Medical Journal. 1988; 64: 85-86.
218. Precocious puberty presenting at 3 months of age. Journal of the Association of Physicians of India 1987; 37
219. A study of severe chronic obstructive airway disease – correlation of clinical features, lung functions, echocardiography, haemodynamic studies by cardiac catheterization and radionuclide studies of right ventricular function. Accepted as a dissertation by Bombay University for the M.D. (Medicine) examination in October, 1986.
220. Homozygous type II – familial hypercholestrolemia – a case report with complete heamodynamic study. Hypertension India. July 1987; 1
221. Radiation necrosis causing failure of automatic ventilation during sleep with periods of central sleep apnea – case report. Chest. 1987; 92: 567-569.
222. Tetanus and its complications: intensive care and management experience in 150 Indian patients. Epidemiology and Infection (formerly the Journal of Hygiene)1987; 99:675–684
Asthma, COPD, Lung infection, Pneumonia, Fluid in lungs, Lung Diseases, Pulmonary Fibrosis, Chronic Bronchitis, Emphysema, Acute Respiratory Tract Infection, Lung Cancer, Pleural effusion, bronchiectasis, Sleep Problem, Sleep Disorder, MDR TB, XDR TB, TB, TDR TB, bronchoscopy, ILD, Pulmonary infections, Difficult asthma, Sleep disorders, COVID